TNGX
Tango Therapeutics, Inc.
stockNASDAQ
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango's programs is an increasingly sophisticated ability to util
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 24.30 | 2026-09-28 | -4.07% | -6.816 |
| 1M | 22.52 | 2026-09-04 | +3.51% | 0.902 |
| 3M | 29.94 | 2026-07-06 | -22.14% | 2.139 |
| 6M | 20.29 | 2026-04-06 | +14.88% | 2.357 |
| 1Y | 7.76 | 2025-10-03 | +200.39% | 1.438 |
| 2Y | 6.98 | 2024-10-04 | +233.95% | — |
| 5Y | 13.45 | 2021-10-04 | +73.31% | 1.312 |
Tango Therapeutics, Inc. (NASDAQ:TNGX) stock price today is $23.31, and today's volume is 5,253,910. TNGX is down 4.663% today. The 30 day average volume is 2.90M. TNGX market cap is $3.93B with 168.61M shares outstanding.